Esperite NV – Strategy, SWOT and Corporate Finance Report

Esperite NV – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company.

Esperite NV (Esperite) is a regenerative and precision medicine company. It collects, processes and stores human adult stem cells obtained from umbilical cord blood and cord tissue. Esperite offers a diagnostic system built on the Next Generation Sequencing technology (NGS) that enables laboratories for performing with bioinformatics-based genetic analysis. The company operates a research and development division, the Cell Factory, which is involved in developing advanced cell therapy medicinal products and new therapies in the field of regenerative medicine. The company works in partnership with pharmaceutical and biotechnology companies to advance the development of its products and services. Esperite is headquartred in Amsterdam, the Netherlands.

Scope

Detailed information on Esperite NV required for business and competitor intelligence needs

A study of the major internal and external factors affecting Esperite NV in the form of a SWOT analysis

An in-depth view of the business model of Esperite NV including a breakdown and examination of key business segments

News about Esperite NV, such as business expansion, restructuring, and contract wins

Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Esperite NV and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Esperite NV as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Esperite NVs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Virgin Health Bank

NHS Cord Blood Bank

New England Cord Blood Bank, Inc

Cryopraxis Criobiologia Ltda

Cells4Life Group LLP

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1 - About the Company 6

Esperite NV - Key Facts 6

Esperite NV - Key Employees 7

Esperite NV - Key Employee Biographies 8

Esperite NV - Major Products and Services 9

Esperite NV - History 10

Esperite NV - Company Statement 13

Esperite NV - Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2 Company Analysis 17

Company Overview 17

Esperite NV - Business Description 18

Business Segment: Genoma 18

Overview 18

Performance 18

Business Segment: Holding 18

Overview 18

Performance 18

Business Segment: Other 18

Overview 18

Performance 18

Business Segment: Stem Cell 18

Overview 18

Performance 19

Business Segment: The Cell Factory 19

Overview 19

Performance 19

Esperite NV - SWOT Analysis 20

SWOT Analysis - Overview 20

Esperite NV - Strengths 20

Esperite NV - Weaknesses 21

Esperite NV - Opportunities 22

Esperite NV - Threats 23

Esperite NV - Key Competitors 24

Section 3 Company Financial Ratios 25

Financial Ratios - Capital Market Ratios 25

Financial Ratios - Annual Ratios 26

Performance Chart 28

Financial Performance 28

Financial Ratios - Interim Ratios 29

Financial Ratios - Ratio Charts 30

Section 4 Company’s Lifesciences Financial Deals and Alliances 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Esperite NV, Recent Deals Summary 33

Section 5 Company’s Recent Developments 34

Nov 23, 2018: ESPERITE : financial results for 2017 are published 34

Sep 13, 2018: Esperite with Cryosave ready to store more than a million samples in its new designed cryostorage facility in geneva 41

Jun 19, 2018: Esperite N.V. secures external financing of up to EUR 5 million to support its commercial activity and development of innovative technologies 42

Jun 11, 2018: European Select Growth Opportunities Fund subscribes to the 19th tranche of its investment today and has agreed to provide up to EUR

7.25 million in additional funding 43

Mar 29, 2018: Esperite, The Cell Factory presents pre-clinical results on the new products of the 2nd generation EV's drugs for treatment of inflammatory diseases 44

Jan 10, 2018: ESPERITE transfers its laboratory activity to Geneva and consequently sells its Belgium loss making subsidiary and avoids EUR 4 millions of future cash out for charges and financial costs 46

Oct 09, 2017: Esperite with CryoSave enters the Ukrainian market and fosters its leadership position in Europe 47

Oct 02, 2017: ESPERITE publishes its half-year report 48

May 31, 2017: ESPERITE Q1 consolidated revenue higher compared to budget 49

May 23, 2017: Esperite Financial Results For 2016 Published 50

Section 6 Appendix 51

Methodology 51

Ratio Definitions 51

About GlobalData 55

Contact Us 55

Disclaimer 55

List of Tables

List of Tables

Esperite NV, Key Facts 6

Esperite NV, Key Employees 7

Esperite NV, Key Employee Biographies 8

Esperite NV, Major Products and Services 9

Esperite NV, History 10

Esperite NV, Subsidiaries 15

Esperite NV, Key Competitors 24

Esperite NV, Ratios based on current share price 25

Esperite NV, Annual Ratios 26

Esperite NV, Annual Ratios (Cont…1) 27

Esperite NV, Interim Ratios 29

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 32

Esperite NV, Recent Deals Summary 33

Currency Codes 51

Capital Market Ratios 51

Equity Ratios 52

Profitability Ratios 52

Cost Ratios 53

Liquidity Ratios 53

Leverage Ratios 54

Efficiency Ratios 54

List of Figures

List of Figures

Esperite NV, Performance Chart (2013 – 2017) 28

Esperite NV, Ratio Charts 30

Esperite NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 31

Esperite NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 32

    Pricing

Discounts available for multiple report purchases.

reportstore@marketline.com
+44 (0) 161 359 5817

Saved reports